UY36202A - Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer - Google Patents
Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncerInfo
- Publication number
- UY36202A UY36202A UY0001036202A UY36202A UY36202A UY 36202 A UY36202 A UY 36202A UY 0001036202 A UY0001036202 A UY 0001036202A UY 36202 A UY36202 A UY 36202A UY 36202 A UY36202 A UY 36202A
- Authority
- UY
- Uruguay
- Prior art keywords
- recombinant hemoglobin
- therapeutic agent
- pharmaceutical composition
- cancer treatment
- subunities
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Una composición farmacéutica que contiene proteína o tetrámero o dímero o subunidad de hemoglobina recombinante para la oxigenación tisular y el tratamiento del cáncer. Un agente terapéutico basado en proteína o tetrámero o dímero o subunidad de hemoglobina recombinante. El resto de hemoglobina recombinante o tetrámero o dímero o su subunidad puede ser dirigido hacia células cancerígenas y el resto terapéutico (agente activo/ fármaco terapéutico) puede matar a las células cancerígenas en forma eficaz. La composición puede utilizarse por sí sola o en combinación con otro(s) agente(s) terapéutico(s) tales como un agente quimioterapéutico, un agente radioterapéutico, un fármaco proteico anticancerígeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462019925P | 2014-07-02 | 2014-07-02 | |
US14/752,999 US9814759B2 (en) | 2014-07-02 | 2015-06-28 | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36202A true UY36202A (es) | 2016-01-29 |
Family
ID=55016241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036202A UY36202A (es) | 2014-07-02 | 2015-07-02 | Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer |
Country Status (12)
Country | Link |
---|---|
US (1) | US9814759B2 (es) |
EP (1) | EP3164412A4 (es) |
KR (1) | KR20170026485A (es) |
CN (1) | CN106715468A (es) |
AR (1) | AR101101A1 (es) |
AU (1) | AU2015283394B2 (es) |
CA (1) | CA2953173A1 (es) |
HK (1) | HK1232242A1 (es) |
SG (2) | SG10201807554QA (es) |
TW (1) | TWI633118B (es) |
UY (1) | UY36202A (es) |
WO (1) | WO2016000616A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016005013A (es) | 2013-10-18 | 2017-02-28 | Deutsches Krebsforsch | Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. |
US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
WO2019003155A1 (en) * | 2017-06-27 | 2019-01-03 | Vision Global Holdings Limited | COMPOSITIONS FOR PHOTODYNAMIC THERAPY AND FLUORESCENCE DIAGNOSIS OF CANCERS AND OTHER DISEASES |
CN110256571A (zh) * | 2018-11-30 | 2019-09-20 | 莱尔芙高新技术(上海)有限公司 | 重组人白蛋白-血红蛋白β亚基融合蛋白 |
US10752672B1 (en) * | 2019-02-01 | 2020-08-25 | Cheer Global Limited | Recombinant hemoglobins and methods of preparation and use thereof |
US20220241765A1 (en) * | 2019-05-24 | 2022-08-04 | Glytech, Inc. | Novel artificial protein catalyst |
WO2021013131A1 (en) * | 2019-07-19 | 2021-01-28 | Cheer Global Limited | Hemoglobin-based therapeutic agents |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4600531A (en) | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
US5449759A (en) | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
US5599907A (en) | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
US6172039B1 (en) * | 1990-04-16 | 2001-01-09 | Apex Bioscience, Inc. | Expression of recombinant hemoglobin and hemoglobin variants in yeast |
JP3426599B2 (ja) * | 1991-11-08 | 2003-07-14 | ヘモゾル インコーポレイテッド | 薬物担体としてのヘモグロビン |
CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
US7338670B2 (en) * | 2005-04-14 | 2008-03-04 | Duke University | Use of an agent that restores tissue perfusion and oxygenation |
US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US8742073B2 (en) | 2010-05-27 | 2014-06-03 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
US8048856B1 (en) | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
TWI610685B (zh) * | 2013-05-13 | 2018-01-11 | 視界全球控股有限公司 | 用於癌症標靶治療及診斷成像之包含經修飾的基於血紅素之治療劑的醫藥組成物 |
-
2015
- 2015-06-28 US US14/752,999 patent/US9814759B2/en active Active
- 2015-06-30 TW TW104121109A patent/TWI633118B/zh not_active IP Right Cessation
- 2015-07-01 WO PCT/CN2015/083041 patent/WO2016000616A1/en active Application Filing
- 2015-07-01 SG SG10201807554QA patent/SG10201807554QA/en unknown
- 2015-07-01 CN CN201580047951.7A patent/CN106715468A/zh active Pending
- 2015-07-01 KR KR1020177001611A patent/KR20170026485A/ko unknown
- 2015-07-01 AU AU2015283394A patent/AU2015283394B2/en not_active Ceased
- 2015-07-01 EP EP15815035.9A patent/EP3164412A4/en not_active Withdrawn
- 2015-07-01 CA CA2953173A patent/CA2953173A1/en not_active Abandoned
- 2015-07-01 SG SG11201610947UA patent/SG11201610947UA/en unknown
- 2015-07-02 UY UY0001036202A patent/UY36202A/es not_active Application Discontinuation
- 2015-07-02 AR ARP150102131A patent/AR101101A1/es unknown
-
2017
- 2017-06-16 HK HK17106011.3A patent/HK1232242A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US9814759B2 (en) | 2017-11-14 |
SG10201807554QA (en) | 2018-10-30 |
HK1232242A1 (zh) | 2018-01-05 |
WO2016000616A1 (en) | 2016-01-07 |
EP3164412A4 (en) | 2018-03-28 |
SG11201610947UA (en) | 2017-01-27 |
US20160000864A1 (en) | 2016-01-07 |
EP3164412A1 (en) | 2017-05-10 |
AR101101A1 (es) | 2016-11-23 |
AU2015283394A1 (en) | 2017-01-19 |
TWI633118B (zh) | 2018-08-21 |
TW201613960A (en) | 2016-04-16 |
KR20170026485A (ko) | 2017-03-08 |
CA2953173A1 (en) | 2016-01-07 |
CN106715468A (zh) | 2017-05-24 |
AU2015283394B2 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36202A (es) | Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer | |
CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
CO2019008364A2 (es) | Composiciones farmacéuticas que comprenden meloxicam | |
SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
CL2018000739A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma. | |
MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
CL2015002736A1 (es) | Composición farmacéutica de clorhidrato de s-ketamina. | |
AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
CR20170361A (es) | Forma de dosificación que incluye una solución sólida de drogas amorfas | |
UY36075A (es) | Derivados de tubulisina | |
MX2024010140A (es) | Nuevos metodos. | |
PE20170392A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
CO2019014671A2 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
MX2015011775A (es) | Uso de levocetirizina y montelukast en el tratamiento de anafilaxis. | |
CL2015001574A1 (es) | Terapia combinada para el cancer | |
AR106351A1 (es) | Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento | |
CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
BR112019022459A2 (pt) | Agente terapêutico para câncer no sangue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220705 |